BEAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HeartBeam Inc (BEAT) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is currently oversold and has a bearish technical trend, with no immediate positive trading signals. While analysts are optimistic about the company's long-term potential and innovative technology, the recent public offering and weak financial performance suggest caution. Holding off on investment until there are clearer signs of financial and market improvement is advisable.
The stock is in a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The MACD is negative and expanding, and the RSI is at 14.075, indicating the stock is oversold. Key support levels are at 0.774, with resistance at 1.059.
Analysts have initiated coverage with Buy ratings and price targets of $4-$5, citing the company's innovative, FDA-cleared ECG system and potential for rapid deployment in cardiology practices. The remote patient monitoring market is a multi-billion-dollar opportunity.
EPS dropped by 16.67% YoY.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $5.3 million, although the loss improved by 8.05% YoY. EPS dropped to -0.15, down 16.67% YoY. Gross margin remains at 0%.
Analysts from Stifel, B. Riley, and D. Boral Capital have initiated Buy ratings with price targets of $4-$5, citing the company's innovative technology and potential for growth in the remote patient monitoring market.
